WEBSITE BSE:544449 NSE: ANTHEM Inc. Year: 2006 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock
Last updated: 15:59
Anthem Biosciences Ltd is one of India’s rapidly growing integrated biopharmaceutical Contract Development and Manufacturing Organisations (CDMO), serving global pharmaceutical, biotechnology and animal health companies. Established in 2006, the company offers end-to-end services through the drug development and manufacturing value chain, from early discovery to commercial-scale manufacturing. With state-of-the-art R&D centres and USFDA/EMA-approved cGMP facilities located in Bengaluru, Anthem Biosciences is focused on: - Small Molecules (A...Read More
Anthem Biosciences Ltd is one of India’s rapidly growing integrated biopharmaceutical Contract Development and Manufacturing Organisations (CDMO), serving global pharmaceutical, biotechnology and animal health companies. Established in 2006, the company offers end-to-end services through the drug development and manufacturing value chain, from early discovery to commercial-scale manufacturing. With state-of-the-art R&D centres and USFDA/EMA-approved cGMP facilities located in Bengaluru, Anthem Biosciences is focused on: - Small Molecules (APIs & Intermediates) - CRDMO Services (Custom Research, Development Testing & Manufacturing) - Biologics & Bioprocess Solutions - Nutraceuticals, Enzymes & Specialty Ingredients - Advanced Chemistry & Synthetic Biology Platform Anthem’s strength lies in its skilled scientific workforce, strong process chemistry expertise and its ability to scale up innovations from lab to pilot, to commercial batches. The company has created a broad client base across the US, Europe and regulated international markets, using its robust compliance, quality systems and record. With the global pharma sector gradually moving to an outsourcing model for R&D and manufacturing, Anthem Biosciences is well positioned to benefit from and meet the growing demand for CDMO services, driven by the cost advantages of India, the innovation ecosystem and the increasing biologics pipeline. Anthem Biosciences continues to grow its capacity and capabilities to be a long-term innovation and manufacturing partner to global life sciences companies. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹41542 Cr.
Stock P/E 92.1
P/B 14.6
Current Price ₹739.6
Book Value ₹ 50.7
Face Value 2
52W High ₹873.3
Dividend Yield 0%
52W Low ₹ 579.5
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Jun 2024 | Sep 2024 | Dec 2024 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|
| Net Sales | 339 | 525 | 498 | 540 | 550 | 423 |
| Other Income | 19 | 28 | 24 | 23 | 48 | 34 |
| Total Income | 358 | 553 | 522 | 563 | 598 | 457 |
| Total Expenditure | 218 | 330 | 338 | 349 | 332 | 266 |
| Operating Profit | 140 | 223 | 184 | 214 | 266 | 191 |
| Interest | 4 | 4 | 3 | 2 | 3 | 0 |
| Depreciation | 19 | 20 | 20 | 26 | 33 | 35 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | -25 |
| Profit Before Tax | 118 | 200 | 161 | 186 | 230 | 130 |
| Provision for Tax | 36 | 38 | 37 | 50 | 56 | 38 |
| Profit After Tax | 82 | 162 | 124 | 136 | 173 | 93 |
| Adjustments | 0 | 0 | -0 | 0 | 0 | 0 |
| Profit After Adjustments | 82 | 162 | 124 | 136 | 173 | 93 |
| Adjusted Earnings Per Share | 1.5 | 2.9 | 2.2 | 2.4 | 3.1 | 1.7 |
| #(Fig in Cr.) | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 82 | 129 | 248 | 308 | 356 | 633 | 1103 | 1231 | 1057 | 1419 | 1845 | 2011 |
| Other Income | 1 | 2 | 3 | 5 | 7 | 21 | 37 | 49 | 85 | 64 | 86 | 129 |
| Total Income | 83 | 130 | 251 | 313 | 363 | 653 | 1140 | 1280 | 1142 | 1483 | 1930 | 2140 |
| Total Expenditure | 58 | 94 | 178 | 215 | 248 | 451 | 696 | 664 | 634 | 914 | 1174 | 1285 |
| Operating Profit | 25 | 36 | 73 | 98 | 115 | 203 | 445 | 616 | 508 | 569 | 757 | 855 |
| Interest | 3 | 4 | 6 | 5 | 5 | 20 | 17 | 12 | 9 | 10 | 11 | 8 |
| Depreciation | 5 | 8 | 10 | 21 | 22 | 62 | 62 | 58 | 64 | 82 | 89 | 114 |
| Exceptional Income / Expenses | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 62 | 0 | 0 | -25 |
| Profit Before Tax | 17 | 25 | 58 | 73 | 88 | 121 | 366 | 546 | 497 | 477 | 657 | 707 |
| Provision for Tax | -0 | 8 | 19 | 23 | 22 | 28 | 94 | 141 | 112 | 110 | 206 | 181 |
| Profit After Tax | 17 | 16 | 39 | 50 | 66 | 93 | 271 | 406 | 385 | 367 | 451 | 526 |
| Adjustments | 0 | -0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 17 | 16 | 39 | 50 | 66 | 93 | 271 | 406 | 385 | 367 | 451 | 526 |
| Adjusted Earnings Per Share | 0.3 | 0.3 | 0.7 | 0.9 | 1.2 | 1.7 | 4.9 | 7.1 | 6.8 | 6.6 | 8.1 | 9.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 30% | 14% | 24% | 37% |
| Operating Profit CAGR | 33% | 7% | 30% | 41% |
| PAT CAGR | 23% | 4% | 37% | 39% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 21% | 22% | 31% | 35% |
| ROCE Average | 29% | 28% | 38% | 34% |
| #(Fig in Cr.) | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 38 | 64 | 102 | 151 | 223 | 422 | 701 | 1355 | 1741 | 1925 | 2410 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 19 | 45 | 51 | 83 | 156 | 95 | 20 | 6 | 96 | 112 | 47 |
| Other Non-Current Liabilities | 1 | 3 | 6 | 3 | 5 | 11 | 14 | 16 | -11 | -18 | 7 |
| Total Current Liabilities | 43 | 69 | 76 | 119 | 126 | 247 | 356 | 349 | 279 | 459 | 485 |
| Total Liabilities | 102 | 181 | 235 | 355 | 510 | 776 | 1091 | 1726 | 2105 | 2477 | 2949 |
| Fixed Assets | 37 | 87 | 91 | 86 | 258 | 306 | 361 | 329 | 449 | 483 | 705 |
| Other Non-Current Assets | 21 | 15 | 37 | 90 | 57 | 67 | 43 | 181 | 217 | 393 | 348 |
| Total Current Assets | 43 | 79 | 107 | 179 | 194 | 403 | 687 | 1216 | 1438 | 1602 | 1896 |
| Total Assets | 102 | 181 | 235 | 355 | 510 | 776 | 1091 | 1726 | 2105 | 2477 | 2949 |
| #(Fig in Cr.) | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 | 0 | 14 | 22 | 41 | 349 | 343 | 184 |
| Cash Flow from Operating Activities | 0 | 0 | 0 | 0 | 0 | 166 | 278 | 333 | 306 | 140 | 418 |
| Cash Flow from Investing Activities | 0 | 0 | 0 | 0 | 0 | -109 | -196 | -205 | -376 | -221 | -152 |
| Cash Flow from Financing Activities | 0 | 0 | 0 | 0 | 0 | -48 | -63 | 181 | 64 | -77 | -134 |
| Net Cash Inflow / Outflow | 0 | 0 | 0 | 0 | 0 | 9 | 18 | 308 | -6 | -158 | 133 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 0 | 0 | 22 | 41 | 349 | 343 | 184 | 317 |
| # | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.34 | 0.3 | 0.71 | 0.91 | 1.21 | 1.7 | 4.92 | 7.11 | 6.75 | 6.57 | 8.07 |
| CEPS(Rs) | 0.44 | 0.44 | 0.9 | 1.3 | 1.61 | 2.83 | 6.05 | 8.12 | 7.87 | 8.03 | 9.67 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 0.77 | 1.08 | 1.79 | 2.68 | 4.06 | 7.75 | 12.72 | 23.75 | 30.51 | 34.43 | 42.49 |
| Core EBITDA Margin(%) | 29.46 | 26.78 | 28.32 | 30.37 | 30.4 | 28.75 | 36.96 | 46.06 | 40.01 | 35.59 | 36.38 |
| EBIT Margin(%) | 24.29 | 22.26 | 25.51 | 25.25 | 26.29 | 22.3 | 34.67 | 45.35 | 47.88 | 34.31 | 36.18 |
| Pre Tax Margin(%) | 20.07 | 19.21 | 23.28 | 23.62 | 24.76 | 19.07 | 33.14 | 44.36 | 47.05 | 33.63 | 35.61 |
| PAT Margin (%) | 20.19 | 12.73 | 15.72 | 16.27 | 18.56 | 14.65 | 24.59 | 32.94 | 36.44 | 25.88 | 24.46 |
| Cash Profit Margin (%) | 26.13 | 18.61 | 19.82 | 22.92 | 24.61 | 24.38 | 30.25 | 37.63 | 42.47 | 31.64 | 29.31 |
| ROA(%) | 16.35 | 11.66 | 18.74 | 16.98 | 15.28 | 14.42 | 29.07 | 28.79 | 20.11 | 16.04 | 16.64 |
| ROE(%) | 44.14 | 34.19 | 49.99 | 41.23 | 36.02 | 28.84 | 48.3 | 39.44 | 24.89 | 20.04 | 20.99 |
| ROCE(%) | 25.6 | 26.7 | 39.87 | 34.59 | 27.35 | 28.38 | 55.36 | 50.94 | 31.08 | 24.21 | 28.55 |
| Receivable days | 43.64 | 56.96 | 64.47 | 83.42 | 80.79 | 51.59 | 59.51 | 86.09 | 103.65 | 98.3 | 93.09 |
| Inventory Days | 68.34 | 66 | 50.36 | 49.58 | 53.59 | 52.86 | 26.55 | 13.83 | 32.4 | 43.81 | 54.59 |
| Payable days | 174.58 | 161.93 | 85.46 | 69.81 | 79.59 | 66.55 | 54.41 | 63.27 | 73.58 | 52.56 | 51.72 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.56 | 0.66 | 0.36 | 0.42 | 0.53 | 0.23 | 0.06 | -0.25 | -0.1 | 0.11 | -0.05 |
| EV/Core EBITDA(x) | 1.86 | 2.32 | 1.21 | 1.31 | 1.65 | 0.71 | 0.15 | -0.49 | -0.2 | 0.28 | -0.13 |
| Net Sales Growth(%) | 0 | 57.01 | 92.77 | 24.27 | 15.49 | 77.75 | 74.36 | 11.6 | -14.16 | 34.29 | 29.96 |
| EBIT Growth(%) | 0 | 44.17 | 119.61 | 23 | 20.26 | 50.78 | 171.1 | 45.96 | -9.37 | -3.76 | 37.05 |
| PAT Growth(%) | 0 | -0.82 | 136.8 | 28.57 | 31.79 | 40.29 | 192.65 | 49.48 | -5.02 | -4.64 | 22.86 |
| EPS Growth(%) | 0 | -11.3 | 134.96 | 28.83 | 32.08 | 40.92 | 189.04 | 44.52 | -5.03 | -2.69 | 22.85 |
| Debt/Equity(x) | 1.07 | 1.16 | 0.76 | 0.79 | 0.85 | 0.38 | 0.14 | 0.03 | 0.07 | 0.12 | 0.05 |
| Current Ratio(x) | 1 | 1.14 | 1.41 | 1.51 | 1.54 | 1.63 | 1.93 | 3.48 | 5.16 | 3.49 | 3.91 |
| Quick Ratio(x) | 0.64 | 0.69 | 0.92 | 1.12 | 1.08 | 1.12 | 1.83 | 3.32 | 4.69 | 3.03 | 3.21 |
| Interest Cover(x) | 5.76 | 7.3 | 11.47 | 15.53 | 17.24 | 6.91 | 22.55 | 45.81 | 58.01 | 50.43 | 63.4 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Jul 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Promoter | 74.69 | 74.69 | 74.69 | 74.68 |
| FII | 1.5 | 1.67 | 1.36 | 1.28 |
| DII | 3.6 | 7.22 | 7.6 | 11.55 |
| Public | 20.22 | 16.42 | 16.35 | 12.5 |
| Others | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 |
| # | Jul 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Promoter | 41.95 | 41.95 | 41.95 | 41.95 |
| FII | 0.84 | 0.94 | 0.77 | 0.72 |
| DII | 2.02 | 4.06 | 4.27 | 6.49 |
| Public | 11.35 | 9.22 | 9.18 | 7.02 |
| Others | 0 | 0 | 0 | 0 |
| Total | 56.16 | 56.16 | 56.16 | 56.17 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
